AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst
March 11, 2024 2:01 PM EDTOn Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the Alzheimer's Disease (AD) treatment landscape. The competitive dynamics have shifted significantly, potentially benefiting Biogen's AD drug, Leqembi, which is developed in partnership with Eisai. Eisai has reported progress on multiple fronts for Leqembi, while a competitor, Eli Lilly, announced an unexpected delay for its AD drug,... More
